Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (September 24-26).
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a niche segment has exploded into a multi-billion-dollar arena, driven by highly effective new medications, primarily GLP-1 receptor agonists, that are
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy. The study met both co-primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus. Overall survival (OS) data were immature, but a clear positive trend was observed. Follow-up continues to the next OS analysis. The giredestrant combination was well tolerated. Adverse events were consistent with the known safety profiles of the individual study treatments, and no new safety signals were observed. This is the first positive head-to-head Phase III trial investigating an all-oral selective estrogen receptor degrader-containing regimen versus a standard of care combination.
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient expectations. This dynamic environment is not merely reshaping how medical services are delivered, but fundamentally redefining the entire patient experience and the
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab-svoa), presented at the 25th Euretina Congress in Paris, France. Data from the open-label AVONELLE-X study reinforce the efficacy, safety and durability of Vabysmo over four years in wet age-related macular degeneration (AMD), a leading cause of vision loss. In the single-arm SALWEEN study, Vabysmo showed clinically meaningful vision gains and retinal drying over one year in polypoidal choroidal vasculopathy (PCV), a vision-threatening subtype of wet AMD that is especially common in Asia.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA Phase II program, including KARDIA-1, KARDIA-2 and the most recent KARDIA-3 study evaluating the efficacy and safety of zilebesiran in patients with uncontrolled hypertension and high cardiovascular (CV) risk, on two to four standard of care antihypertensives. In particular, KARDIA-3 aimed to define the patient population to be investigated in the Phase III CV outcomes trial.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 700,000-square-foot facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity. The event was attended by federal, state and local officials, including U.S. Rep. Deborah Ross, North Carolina Gov. Josh Stein, State Sec. of Commerce Lee Lilley, State Sens. Sydney Batch and Lisa Grafstein, State Rep. Erin Paré, Wake County Commissioner Cheryl Stallings and Holly Springs Mayor Sean Mayefskie.
